Company / SG&A Expense
ELITE PHARMACEUTICALS INC /NV/ SG&A Expense History
FY2016-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$9.0M
FY2024
5-year range
$4.5M / $9.0M
FY2020-FY2024
Trend
+26.0%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
SG&A Expense has increased for 4 consecutive years, from $3M in FY2020 to $9M in FY2024.
Based on SEC 10-K filings.
$9M in FY2024 with a 5-year CAGR of +21.9%.
Increased from $5M to $9M over the past 2 years.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +26.3%
- 5-Year CAGR
- +21.9%
- 10-Year CAGR
- -
Key checks
Key Insights
- ELITE PHARMACEUTICALS INC /NV/'s sg&a expense has grown for 4 consecutive years.
- 5-year CAGR of +21.9%, indicating consistent growth.
- In FY2024, sg&a expense increased 26.0% year-over-year.
- Lowest sg&a expense in the period was in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -0.19 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | $9.0M | +26.0% |
| FY2023 | $7.1M | +39.5% |
| FY2022 | $5.1M | +14.7% |
| FY2021 | $4.5M | +34.3% |
| FY2020 | $3.3M | -0.8% |
| FY2019 | $3.3M | +8.6% |
| FY2018 | $3.1M | +32.2% |
| FY2017 | $2.3M | +12.0% |
| FY2016 | $2.1M | -28.2% |
As of FY2024 · SEC 10-K · Updated Jun 29, 2026